Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Exercise Physiology

Background:

• Peripheral artery disease, specifically intermittent claudication, significantly impairs quality of life.
• Current treatments for claudication have limitations, necessitating exploration of novel therapeutic agents.
• Propionyl-L-carnitine is an endogenous compound involved in energy metabolism, with potential benefits in conditions of impaired circulation.

Purpose of the Study:

• To evaluate the efficacy of propionyl-L-carnitine in improving peak walking time in patients with claudication.
• To assess the effects of propionyl-L-carnitine on claudication onset time and functional status.
• To determine the safety profile of propionyl-L-carnitine in this patient population.

Main Methods:

• A 6-month, double-blind, randomized, placebo-controlled trial involving 155 patients with claudication.
• Participants received either propionyl-L-carnitine (2g/day) or a placebo.
• Exercise performance was assessed using a graded treadmill test, and functional status was evaluated via validated questionnaires.

Main Results:

• Propionyl-L-carnitine significantly increased peak walking time by 54% compared to a 25% increase in the placebo group (P <0.001).
• Improvements were also observed in claudication onset time, walking distance, and walking speed.
• The treatment group showed enhanced physical role functioning, reduced bodily pain, and improved health transition scores, with no significant difference in adverse events.

Conclusions:

• Propionyl-L-carnitine safely and effectively improves exercise capacity in patients with claudication.
• The supplement enhances functional status, offering a promising non-invasive therapeutic option.
• Further research may elucidate the precise mechanisms of action and long-term benefits.